Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Real-world data on melanoma brain metastases and survival outcome

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The molecular profile of mucosal melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Global microRNA profiling of metastatic conjunctival melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Targeted ultrasound and fine-needle aspiration cytology for sentinel node diagnostics in early-stage melanoma: a validation study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Prognostic and predictive value of YKL-40 in stage IIB-III melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Novel medical therapies have revolutionized outcome for patients with melanoma. However, patients with melanoma brain metastases (MBM) still have poor survival. Data are limited as these patients are generally excluded from clinical trials, wherefore real-world data on clinical outcome may support evidence-based treatment choices for patients with MBM. Patients diagnosed with MBM between 2008 and 2020 were included retrospectively. Patient characteristics, treatment, and outcome data were recorded from The Danish Metastatic Melanoma Database, pathology registries, electronic patient files, and radiation plans. Anti-programmed cell death protein 1 antibodies and the combination of BRAF/MEK-inhibitors were introduced in Denmark in 2015, and the cohort was split accordingly for comparison. A total of 527 patients were identified; 148 underwent surgical excision of MBM, 167 had stereotactic radiosurgery (SRS), 270 received whole-brain radiation therapy (WBRT), and 343 received systemic therapies. Median overall survival (mOS) for patients diagnosed with MBM before and after 2015 was 4.4 and 7.6 months, respectively. Patients receiving surgical excision as first choice of treatment had the best mOS of 10.9 months, whereas patients receiving WBRT had the worst outcome (mOS, 3.4 months). Postoperative SRS did not improve survival or local control after surgical excision of brain metastases. Of the 40 patients alive >3 years after diagnosis of MBM, 80% received immunotherapy at some point after diagnosis. Patients with meningeal carcinosis did not benefit from treatment with CPI. Outcome for patients with MBM has significantly improved after 2015, but long-term survivors are rare. Most patients alive >3 years after diagnosis of MBM received immunotherapy.

OriginalsprogEngelsk
TidsskriftMelanoma Research
Vol/bind32
Udgave nummer3
Sider (fra-til)173-182
Antal sider10
ISSN0960-8931
DOI
StatusUdgivet - 1 jun. 2022

Bibliografisk note

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

ID: 75713505